Two are better than one on progression through MET mechanism for EGFR+ NSCLC patients

Affiliations

Editorial

Waleed Kian et al. Transl Lung Cancer Res. 2018 Dec.

. 2018 Dec;7(Suppl 4):S334-S335.

doi: 10.21037/tlcr.2018.12.01.

¹ The Legacy Heritage Oncology Center & Dr. Larry Norton Institute, Soroka Medical Center & Ben-Gurion University, Beer-Sheva, Israel.

No abstract available

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer.
Wu YL, Zhang L, Kim DW, Liu X, Lee DH, Yang JC, Ahn MJ, Vansteenkiste JF, Su WC, Felip E, Chia V, Glaser S, Pultar P, Zhao S, Peng B, Akimov M, Tan DSW. Wu YL, et al. J Clin Oncol. 2018 Nov 1;36(31):3101-3109. doi: 10.1200/JCO.2018.77.7326. Epub 2018 Aug 29. J Clin Oncol. 2018. PMID: 30156984 Clinical Trial.

1. Kim S, Kim TM, Kim DW, et al. Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib. Cancer Res Treat 2018. [Epub ahead of print]. 10.4143/crt.2018.052 - DOI - PMC - PubMed
1. Yao D, Dai C, Peng S. Mechanism of the mesenchymal-epithelial transition and its relationship with metastatic tumor formation. Mol Cancer Res 2011;9:1608-20. 10.1158/1541-7786.MCR-10-0568 - DOI - PubMed
1. Wu YL, Soo RA, Locatelli G, et al. Does c-Met remain a rational target for therapy in patients with EGFR TKI-resistant non-small cell lung cancer?. Cancer Treat Rev 2017;61:70-81. 10.1016/j.ctrv.2017.10.003 - DOI - PubMed
1. Nagano T, Tachihara M, Nishimura Y. Mechanism of Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors and a Potential Treatment Strategy. Cells 2018;7. - PMC - PubMed
1. Yano S, Wang W, Li Q, et al. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res 2008;68:9479-87. 10.1158/0008-5472.CAN-08-1643 - DOI - PubMed